Flagship explainer

How Kiniksa Pharmaceuticals International, plc makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$678M · 100%Cost of revenue$77.7M · 11%Gross profit$600M · 89%Operating income$77.2M · 11%Income before tax$88.9M · 13%Income tax$29.9M · 4%Net income$59M · 9%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$678M100%
Cost of revenue$77.7M11%
$600M89%
$77.2M11%
Income before tax$88.9M13%
Income tax$29.9M4%
$59M9%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

View the full Kiniksa Pharmaceuticals International, plc analysis at Buy Like Buffett